-+ 0.00%
-+ 0.00%
-+ 0.00%

APNIMED - AD109 GENERALLY WELL-TOLERATED IN PHASE 3 TRIALS WITH COMMON ADVERSE EVENTS DRY MOUTH, INSOMNIA, NAUSEA

Reuters·07/14/2026 12:00:09

Please log in to view news